Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 1101-1107

  Dong, Min ^a   Fan, Xin Juan ^a   Chen, Zhan Hong ^a   Wang, Tian Tian ^a   Li, Xing ^a   Chen, Jie ^a   Lin, Qu ^a   Wen, Jing Yun ^a   Ma, Xiao Kun ^a   Wei, Li ^a   Ruan, Dan Yun ^a   Lin, Ze Xiao ^a   Liu, Quentin ^b,c   Wu, Xiang Yuan ^a   Wan, Xiang Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; EZH2; HIF 1 ; Prognosis

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOCAL FAILURE FREE SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT DURATION; WESTERN BLOTTING; BREAST TUMOR; LEUKEMIC INFILTRATION; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIC INFILTRATION; MCF-7 CELLS; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84923068328     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3322     Document Type: Article

References (39)

1. Fujii S, Ito K, Ito Y and Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
2. Du J, Li L, Ou Z, et al: FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat 131: 65-73, 2012.
3. Cao Q, Yu J, Dhanasekaran SM, et al: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284, 2008.
4. Bachmann IM, Halvorsen OJ, Collett K, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006. (Pubitemid 46622055)
5. Richter GH, Plehm S, Fasan A, et al: EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106: 5324-5329, 2009.
6. Au SL, Wong CC, Lee JM, et al: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56: 622-631, 2012.
7. Ren G, Baritaki S, Marathe H, et al: Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 72: 3091-3104, 2012.
8. Granit RZ, Gabai Y, Hadar T, et al: EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene 32: 3886-3895, 2013.
9. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003. (Pubitemid 37205983)
10. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H and Mori M: Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31: 376-380, 2005. (Pubitemid 40521303)
11. Yonemitsu Y, Imazeki F, Chiba T, et al: Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 40: 1304-1311, 2009.
12. Rao ZY, Cai MY, Yang GF, et al: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31: 1576-1583, 2010.
13. Cao W, Feng Z, Cui Z, et al: Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 118: 2858-2871, 2012.
14. Lee H, Yoon SO, Jeong WY, Kim HK, Kim A and Kim BH: Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol 43: 1704-1710, 2012.
15. Huqun, Ishikawa R, Zhang J, et al: Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 118: 1599-1606, 2012.
16. Collett K, Eide GE, Arnes J, et al: Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-1174, 2006. (Pubitemid 43342505)
17. Athanassiadou AM, Tsipis A, Patsouris E, et al: Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters. Acta Cytol 55: 180-186, 2011.
18. Alford SH, Toy K, Merajver SD and Kleer CG: Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 132: 429-437, 2012.
19. Semenza GL: Regulation of mammalian O 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
20. Schito L, Rey S, Tafani M, et al : Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 109: E2707-E2716, 2012.
21. Schindl M, Schoppmann SF, Samonigg H, et al: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002. (Pubitemid 34633742)
22. Wan XB, Fan XJ, Chen MY, et al: Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 6: 395-404, 2010.
23. Dong M, Wan XB, Yuan ZY, et al: Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. Med Oncol 30: 355, 2013.
24. Cao P, Deng Z, Wan M, et al: MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9: 108, 2010.
25. Wan XB, Fan XJ, Huang PY, et al: Aurora-A activation, correlated with hypoxia-inducible factor-1α, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci 103: 1586-1594, 2012.
26. Park JH, Lee JY, Shin DH, Jang KS, Kim HJ and Kong G: Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1alpha mediated by the PTEN/PI3K/Akt pathway. Oncogene 30: 4578-4589, 2011.
27. Chang CJ, Yang JY, Xia W, et al: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 19: 86-100, 2011.
28. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
29. Fan XJ, Wan XB, Yang ZL, et al: Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Hum Pathol 44: 173-180, 2013.
30. Wan XB, Zhao Y, Fan XJ, et al: Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. PLoS One 7: e31989, 2012.
31. Sauvageau M and Sauvageau G: Polycomb group proteins: multifaceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299-313, 2010.
32. Gong Y, Huo L, Liu P, et al: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117: 5476-5484, 2011.
33. De Brot M, Rocha RM, Soares FA and Gobbi H: Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 44: 303-312, 2012.
34. Pietersen AM, Horlings HM, Hauptmann M, et al: EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109, 2008.
35. Jansen MP, Reijm EA, Sieuwerts AM, et al: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 133: 937-947, 2012.
36. Lee ST, Li Z, Wu Z, et al: Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell 43: 798-810, 2011.
37. Shapochka DO, Zaletok SP and Gnidyuk MI: Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol 34: 358-363, 2012.
38. Wang Y, Yin Q, Yu Q, et al: A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130: 489-498, 2011.
39. Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR and Chi JT: Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 13: R62, 2011.